[Focus on tumor immunology of transitional cell carcinoma].
Olbert
P J
PJ
Klinik fũr Urologie und Kinderurologie, Philipps-Universität Marburg, Marburg.olbert@med.uni-marburg.de
Schrader
A J
AJ
Hegele
A
A
Hofmann
R
R
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000283:Administration, Intravesical; D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004598:Electrosurgery; D006801:Humans; D051379:Mice; D009367:Neoplasm Staging; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000502:physiology; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9